My primary clinical and research focus is epithelial ovarian cancer (EOC), the fifth leading cause of cancer-related mortality in women and the most lethal of all gynecologic tumors. I am using gene expression profiling to identify novel genes involved in malignant transformation and drug resistance, predict the outcome of advanced disease as well as response to novel therapies, and molecularly characterize a variety of EOC histologic subtypes. This involves a combination of data analysis as well as in vitro work with a special focus on elucidating platinum resistance as well as improving EOC prognostication. My translational research efforts in this area have been supported by the Department of Defense Ovarian Cancer Research Program, the American Association of Cancer Research (AACR), as well as the Clinical Investigator Training Program from Harvard Medical School and MIT. As a clinical researcher, I am also involved as a overall principal investigator (PI) in DFHCC-wide clinical trials as well as site PI at DFCI in DFHCC-wide clinical trials.